| 摘要 |
Disclosed is a use of a HER2 antibody that inhibits HER dimerization more effectively than Trastuzumab, in the preparation of a medicament for treating a platinum-resistant cancer selected from the group consisting of ovarian cancer, primary peritoneal carcinoma and fallopian tube carcinoma, wherein the medicament further comprises an antimetabolite chemotherapeutic agent, wherein the HER2 antibody binds to Domain II of HER2.
|
